De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: Molecular mechanisms and correlation with rituximab sensitivity

CD20 is expressed in most B-cell lymphomas and is a critical molecular target of rituximab. Some B-cell lymphomas show aberrant CD20 expression, and rituximab use in these patients is controversial. Here we show both the molecular mechanisms and the clinical significance of de novo diffuse large B-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Tokunaga, Takashi, Tomita, Akihiro, Sugimoto, Keiki, Shimada, Kazuyuki, Iriyama, Chisako, Hirose, Tatsuya, Shirahata-Adachi, Mizuho, Suzuki, Yasuhiro, Mizuno, Hiroki, Kiyoi, Hitoshi, Asano, Naoko, Nakamura, Shigeo, Kinoshita, Tomohiro, Naoe, Tomoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317883/
https://www.ncbi.nlm.nih.gov/pubmed/24147568
http://dx.doi.org/10.1111/cas.12307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317883/
https://www.ncbi.nlm.nih.gov/pubmed/24147568
http://dx.doi.org/10.1111/cas.12307

Ejemplares similares